ECM
ADXN

Endurant Capital Management’s Addex Therapeutics ADXN Stock Holding History

Endurant Capital Management’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,037
Closed -$114K – 36
2023
Q1 		$114K Buy
+6,037
New +$153K 0.06% 48

Other funds holding ADXN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Endurant Capital Management's ADXN Position: Q2 2023 in Review

Endurant Capital Management sold out of Addex Therapeutics (ADXN) in Q2 2023, closing a stake of 6,037 shares — an estimated $114K sold.

Endurant Capital Management first reported a position in ADXN in Q1 2023 and held it in 1 quarter. The position peaked at $114K in Q1 2023. 3 funds tracked by Wall St. Rank hold ADXN as of Q2 2023.

  • Endurant Capital Management reported no remaining Addex Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Endurant Capital Management sold 6,037 Addex Therapeutics shares in Q2 2023, an estimated $114K.
  • Endurant Capital Management first reported a position in Addex Therapeutics in Q1 2023 and held it in 1 quarter.
  • Endurant Capital Management's Addex Therapeutics position peaked at $114K in Q1 2023.
  • 3 funds tracked by Wall St. Rank held Addex Therapeutics as of Q2 2023.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.